Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Alcohol Dependence Drug Exhibits Positive Findings in Study

By Globe Newswire | January 24, 2017

MediciNova announces publication of positive findings on MN-166 (ibudilast) in alcohol dependence.

MediciNova, Inc. announced that the medical journal Neuropsychopharmacology has published a new article on MN-166 (ibudilast) written by Dr. Lara Ray and colleagues at the University of California, Los Angeles. The article reports that MN-166 (ibudilast) was associated with mood improvements on the stress- and alcohol-cue exposures, as well as reductions in overall craving, depression and anxiety for alcohol in subjects diagnosed with alcohol use disorder (AUD).  Moreover, in the subjects that had higher depressive symptomatology, MN-166 (ibudilast) reduced the stimulant and mood-altering effects of alcohol compared to placebo.

Major findings from the publication, “Development of the Neuroimmune Modulator Ibudilast for the Treatment of Alcoholism: A Randomized, Placebo-Controlled, Human Laboratory Trial,” include the following:

In an intravenous alcohol challenge session in subjects reporting higher levels of depressive symptomatology as measured by the Beck Depressive Inventory (BDI) Scale:  

  • ibudilast significantly decreased the alcohol-induced stimulation (p < 0.05),
  • ibudilast significantly decreased alcohol-induced positive mood (p < 0.05),
  • ibudilast significantly decreased ‘wanting’ of alcohol (p < 0.05), and
  • ibudilast showed a trend to decreased ‘liking’ of alcohol (p = 0.06).

While ibudilast decreased the alcohol-induced rewarding effects described above during the alcohol challenge, it also increased negative mood responses to alcohol (p < 0.05) in subjects reporting higher levels of depressive symptomatology on the BDI.

Overall, MN-166 (ibudilast) was well tolerated.  There were no severe adverse events and there were no study dropouts directly related to MN-166 (ibudilast).

About the Clinical Trial

This randomized, double-blind, placebo-controlled study enrolled 24 non-treatment seeking individuals with either alcohol abuse or dependence in a UCLA research unit. Participants were randomly assigned to a 7-day treatment period involving repeat oral administration of either MN-166 (ibudilast) escalated up to 100 mg/day or placebo. During the treatment period, participants were administered the study medication, completed an IV alcohol challenge, and took part in laboratory tests of alcohol craving as well as mood assessments and standard safety tests. Following a 7-10 day study break, trial participants re-enrolled for another 7-day period wherein they crossed over to the other treatment condition. The key study outcomes included safety, tolerability and preliminary efficacy as indicated by whether MN-166 (ibudilast) reduced alcohol craving and the rewarding effects of alcohol under controlled experimental conditions of cue exposure and alcohol administration. 

About MN-166 (ibudilast)

MN-166 (ibudilast) has been marketed in Japan and Korea since 1989 to treat post-stroke complications and bronchial asthma. MediciNova is developing MN-166 for progressive MS and other neurological conditions such as ALS and drug use disorders. MN-166 (ibudilast) is a first-in-class, orally bioavailable, small molecule phosphodiesterase (PDE) -4 and -10 inhibitor and a macrophage migration inhibitory factor (MIF) inhibitor that suppresses pro-inflammatory cytokines and promotes neurotrophic factors. It attenuates activated glia cells, which play a major role in certain neurological conditions. Ibudilast’s anti-neuroinflammatory and neuroprotective actions have been demonstrated in preclinical and clinical study results and provide the rationale for its therapeutic utility in neurodegenerative diseases (e.g., progressive MS and amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease), substance abuse/addiction and chronic neuropathic pain.

(Source: Globe Newswire)

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!


Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE